Sugi Predict

Sugi Predict / Compounds / SCHEMBL1823637

SCHEMBL1823637

SCHEMBL1823637

COC(=O)C[C@H](O)C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.43
▸ MGAM O43451 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ SI P14410 2/20 0.40
▸ MGAM2 Q2M2H8 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CA14 Q9ULX7 2/20 0.33
▸ TET2 Q6N021 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ABCB1 P08183 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ZDHHC7 Q9NXF8 1/20 0.32
▸ CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205700 1.00 TSHR (0.43) TSHRMGAMGAASIMGAM2
SCHEMBL1691025 1.00 TSHR (0.43) TSHRMGAMGAASIMGAM2
SCHEMBL27676625 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
SCHEMBL28184474 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
Ammonia Solution, Strong SCHEMBL21219093 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
Hydrochloric Acid SCHEMBL28250071 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
SCHEMBL6061378 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
SCHEMBL6061384 0.98 TSHR (0.42) TSHRMGAMGAASIMGAM2
SCHEMBL31681670 0.91 TSHR (0.37) TSHRMGAMGAASIMGAM2
SCHEMBL30565813 0.88 MGAM (0.37) TSHRMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113480497-B Synthetic method of empagliflozin key intermediate 山东铂源药业股份有限公司 2023-02-28 — — CN claimed
US-12590117-B2 Hexose derivatives, preparation and uses thereof FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) 2026-03-31 — — US disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
WO-2025134071-A1 MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS SANOFI (FR) 2025-06-26 — — WO disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
EP-4377308-A1 COMPOUNDS FOR COMPLEXATION OF RARE EARTH ELEMENTS AND/OR S-, P-, D- BLOCK METALS, THEIR COORDINATION COMPOUNDS, PEPTIDE CONJUGATES, METHOD OF THEIR PREPARATION AND USE THEREOF Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) 2024-06-05 — — EP disclosed
US-20240116943-A1 TETRAHYDROBENZOFURODIAZEPINONE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2024-04-11 — — US disclosed
CN-117800939-A Characteristic impurities in enggliflozin bulk drug or preparation and application thereof 浙江宏元药业股份有限公司 2024-04-02 — — CN disclosed
US-6235753-B1 TUMOR NECROSIS FACTOR; AUTOIMMUNE DISEASES; ANTIALLERGENS SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-22 — — US disclosed
EP-1077970-A1 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 — — EP disclosed
US-6110962-A FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 — — US disclosed
WO-1999058521-A1 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 — — WO disclosed
CN-1234016-A Process for prepn. of butane triols ZENECA LTD (GB) 1999-11-03 — — CN disclosed
CN-1224415-A Inhibitors of s-CD 23 production and TNF secretion SMITHKLINE BEECHAM PLC (GB) 1999-07-28 — — CN disclosed
EP-0923516-A1 PROCESS FOR THE PREPARATION OF BUTANE TRIOLS ZENECA LIMITED (GB) 1999-06-23 — — EP disclosed
EP-0918747-A1 INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF SMITHKLINE BEECHAM PLC (GB) 1999-06-02 — — EP disclosed
WO-1998008793-A1 PROCESS FOR THE PREPARATION OF BUTANE TRIOLS ZENECA LIMITED (GB) 1998-03-05 — — WO disclosed
WO-1997043249-A1 INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF SMITHKLINE BEECHAM PLC (GB) 1997-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116943-A1 TETRAHYDROBENZOFURODIAZEPINONE COMPOUND AND PHARMACEUTICAL USE THEREOF PIM1, PIM2, PIM3 TSHR 3453/4885MGAM 1260/4885GAA 792/4885
US-12590117-B2 Hexose derivatives, preparation and uses thereof SLC5A1, HK1, SLC5A2 TSHR 1829/4885MGAM 1018/4885GAA 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.